Author Archives : Editorial Team

Home  >>  Author : Editorial Team

Sciomics participates in collaborative clinical trials for the treatment of metaphyseal chondrodysplasia type Schmid (MCDS)

On February 12, 2018, Posted by , In News, With Comments Off on Sciomics participates in collaborative clinical trials for the treatment of metaphyseal chondrodysplasia type Schmid (MCDS)

Heidelberg, 12th February, 2018 Multinational consortium has been granted 5.7 Million Euro for the development of novel therapeutic approaches in rare skeletal disorders. Sciomics’ expertise with the antibody microarray technology herein serves as a valuable tool for biomarker identification and personalized treatment monitoring. The biotechnology company Sciomics GmbH, located in…

Slovakia becomes EMBL member state

On February 8, 2018, Posted by , In News, With Comments Off on Slovakia becomes EMBL member state

EMBL welcomes Slovakia as its 24th member state EMBL welcomed Slovakia as its latest member state on 29 January 2018. The accession of the Slovak Republic to EMBL emphasises the organisation’s commitment to promoting European science and collaboration among researchers. As a member state, Slovakia will receive access to all…

Two Excellent Young Researchers Honoured in Heidelberg

On February 8, 2018, Posted by , In News, With Comments Off on Two Excellent Young Researchers Honoured in Heidelberg

Marieke Essers and Theodore Alexandrov have received Chica and Heinz Schaller Award for basic biomedical research Photo: Rothe Chica und Heinz Schaller Award for basic biomedical research: Dr Marieke Essers (second from right) and Dr Theodore Alexandrov (centre) receiving the award. The award was handed over by the foundation’s Chairperson,…

Affimed Reports New Data for AFM13 from Two Separate Clinical Trials in Hodgkin and CD30-Positive Lymphomas

On February 8, 2018, Posted by , In News, With Comments Off on Affimed Reports New Data for AFM13 from Two Separate Clinical Trials in Hodgkin and CD30-Positive Lymphomas

Heidelberg, Germany, February 1, 2018 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today reported additional preliminary patient data from two separate clinical studies of its lead NK cell engager candidate AFM13. The data demonstrate that AFM13 was well-tolerated…

Sanofi to acquire Ablynx for €3.9 Billion

On January 30, 2018, Posted by , In Press Releases, With Comments Off on Sanofi to acquire Ablynx for €3.9 Billion

Strengthens Sanofi’s R&D strategy with innovative Nanobody® technology platform Expands growing rare blood disorders franchise with Ablynx’s late-stage investigational caplacizumab aTTP treatment Unanimously approved by Sanofi and Ablynx Boards of Directors Paris, France and Ghent, Belgium – January 29, 2018 – Sanofi and Ablynx, a biopharmaceutical company engaged in the…

DKFZ/Heidelberg University Hospital: Kristian Pajtler received $100,000 award for brain cancer research

On January 30, 2018, Posted by , In Press Releases, With Comments Off on DKFZ/Heidelberg University Hospital: Kristian Pajtler received $100,000 award for brain cancer research

Kristian Pajtler, a pediatric oncologist from the “Hopp Children’s Cancer Center at the NCT Heidelberg” (KiTZ), received the 2018 CERN Scientific Fellowship Award with a monetary prize of 100,000 US dollars. Pajtler has been awarded the distinction for his work on ependymoma, a rare type of brain cancer. The “Hopp…

DKFZ: A weak heart due to metabolic change

On January 24, 2018, Posted by , In Press Releases, With Comments Off on DKFZ: A weak heart due to metabolic change

The heart derives its energy primarily from fatty acids. However, if a metabolic shift to other energy sources takes place, this can result in congestive heart failure, scientists from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital have now discovered. This underscores the role of metabolism in heart…

DKFZ: Starving Tumors: New Target Discovered

On January 24, 2018, Posted by , In Press Releases, With Comments Off on DKFZ: Starving Tumors: New Target Discovered

Actively growing tumors have a high demand for oxygen and nutrients. Therefore, they stimulate the growth of blood vessels. This process is called angiogenesis. If tumor-associated angiogenesis is suppressed, this may limit tumor growth. Scientists from the German Cancer Research Center and the European Center for Angioscience at Heidelberg University…

Heidelberg University: Heidelberg researchers obtain grant from Baden-Württemberg Foundation – Blood-Brain Barrier on a Chip

On January 24, 2018, Posted by , In News, With Comments Off on Heidelberg University: Heidelberg researchers obtain grant from Baden-Württemberg Foundation – Blood-Brain Barrier on a Chip

Replicating the Blood-Brain Barrier on a Chip Heidelberg researchers obtain grant from Baden-Württemberg Foundation A new research project at Heidelberg University aims to replicate the blood-brain barrier as a model on a chip, thereby enabling the transport of drugs into the brain. A research team under Prof. Dr Gert Fricker…

DKFZ: Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

On January 19, 2018, Posted by , In Press Releases, With Comments Off on DKFZ: Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem…